Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

The following is a summary of “Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...

In this section, we will analyze the mechanisms attributed to BCG cancer immunotherapy for bladder cancer. Over 100 years ago, pathological studies unearthed an association between mycobacterial ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

Discover how a groundbreaking study links cholesterol-lowering therapy to reduced bladder cancer growth offering hope for ...

Bladder cancer often begins with subtle symptoms that are easy to overlook. The most common early sign is blood in the urine, a condition known as hematuria. In many cases, the blood may not always be ...

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients ...

Outcome of BCG immunotherapy of bladder cancer may ultimately depend on imbalance of Th1/Th17–Th2–regulatory T-cell axis. It is important to determine the expression and potential role of ...